FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1041-1043 March 10, 2005 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Taylor, A. L. PubMed Citation

To the Editor: Taylor et al. (Nov. 11 issue)¹ show that isosorbide dinitrate plus hydralazine increased survival in a group of black patients with heart failure. The authors state that a retrospective analysis of the Vasodilator Heart Failure Trial (VHeFT) studies² identified black patients with heart failure as the group benefiting from this therapy.

Black patients in the V-HeFT cohorts had a lower prevalence of a history of coronary artery disease and a higher prevalence of a history of hypertension than did white patients (Table 1). These differences indicate proportional differences in the causes of heart failure in . . . [Full Text of this Article]

This article has been cited by other articles:

• Kahn, J. (2008). Exploiting Race in Drug Development: BiDil's Interim Model of Pharmacogenomics. Social Studies of Science 38: 737-758 [Abstract]  
• Bibbins-Domingo, K., Fernandez, A. (2007). BiDil for Heart Failure in Black Patients: Implications of the U.S. Food and Drug Administration Approval. ANN INTERN MED 146: 52-56 [Abstract] [Full Text]  
• Barr, D. A. (2005). The Practitioner's Dilemma: Can We Use a Patient's Race To Predict Genetics, Ancestry, and the Expected Outcomes of Treatment?. ANN INTERN MED 143: 809-815 [Abstract] [Full Text]